Skip to content
Screener

Biohaven BHVN Total Liabilities

Total Liabilities at other companies

Xenon Pharmaceuticals logo
Xenon PharmaceuticalsXENE
$53.38M+32.4%
Rapport Therapeutics, Inc. logo
Rapport Therapeutics, Inc.RAPP
$36.06M+64.0%
Vir Biotechnology, Inc. logo
Vir Biotechnology, Inc.VIR
$232.31M-5.2%
Monte Rosa Therapeutics, Inc. logo
Monte Rosa Therapeutics, Inc.GLUE
$203.88M+123%
Avalo Therapeutics logo
Avalo TherapeuticsAVTX
$42.12M+91.4%
Kymera Therapeutics logo
Kymera TherapeuticsKYMR
$136.19M-14.7%

Other financials

Income statement

See full
Operating income-$130.4M+41.1%
Net income-$130.5M+41.1%
EPS (diluted)-$0.88+59.4%

Balance sheet

See full
Cash & equivalents$277.1M+170%
Total debt$286.2M+706%
Total equity$129.5M-50.1%
Total assets$466.4M+1.6%

Cash flow

See full
Operating cash flow-$149.9M+9.2%
CapEx--100%
Free cash flow-$149.9M+9.5%

Valuation

See full
Market cap$2.19B+45.4%
Enterprise value$2.2B+35.1%

Returns & leverage

See full
Return on equity-333%+17.9pp
Debt / equity2.2×+2.1×
Current ratio7.4×+5.1×

Where this comes from

Reported directly by Biohaven in its filing.

Tagged under the XBRL concept us-gaap:Liabilities.

The source filing: Biohaven’s 10-Q, filed May 4, 2026.

Filed
May 4, 2026, 4:07 PM EDT
Fiscal quarter
Q1 FY2026
Calendar quarter
Q1 2026
Accession
0001935979-26-000045
Line itemMarch 31, 2026December 31, 2025
Non-current operating lease liability38,36339,958
Notes payable241,912238,900
Other non-current liabilities4,5564,583
Total liabilities336,906399,375
Commitments and contingencies (Note 12)
Shareholders' (Deficit) Equity:
Preferred shares, no par value; 10,000,000 shares authorized, no shares issued and outstanding as of March 31, 2026 and December 31, 2025
Common shares, no par value; 200,000,000 shares authorized as of March 31, 2026 and December 31, 2025; 150,506,490 and 132,775,113 shares issued and outstanding as of March 31, 2026 and December 31, 2025, respectively2,132,9081,934,276

Item 1. Unaudited Condensed Consolidated Financial Statements

FAQ

What is Biohaven's total liabilities?
Biohaven (BHVN) reported total liabilities of $336.91M in Q1 2026.
How has Biohaven's total liabilities changed year-over-year?
Biohaven's total liabilities increased by 68.9% year-over-year, from $199.45M to $336.91M.
What is the long-term trend for Biohaven's total liabilities?
Over 4 years (2021 to 2025), Biohaven's total liabilities has grown at a 70.4% compound annual growth rate (CAGR), from $47.37M to $399.38M.
What does total liabilities mean?
The sum of all current and non-current obligations — everything the company owes to creditors, employees, governments, and other stakeholders.

Ask your AI about Biohaven's total liabilities.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude